Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Mark Jesus M MagbanuaZiad AhmedRosalyn W SayamanLamorna Brown SwigartGillian L HirstChristina YauDenise M WolfWen LiAmy L DelsonJane PerlmutterPaula R PohlmannWilliam Fraser SymmansDouglas YeeNola M HyltonLaura J EssermanAngela M DeMicheleHope S RugoLaura van 't VeerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA.